Login / Signup

Cost-effectiveness analysis of 3 months of weekly rifapentine and isoniazid compared to isoniazid monotherapy in a Canadian arctic setting.

Christopher PeaseGonzalo AlvarezRanjeeta MallickMike PattersonSandy FinnYahya HabisKevin SchwartzmanElaine KilabukSunita MulpuruAlice Zwerling
Published in: BMJ open (2021)
In a remote Canadian arctic setting, using 3HP instead of 9H for LTBI treatment may result in cost savings and similar or improved health outcomes.
Keyphrases
  • mycobacterium tuberculosis
  • climate change
  • combination therapy
  • open label
  • randomized controlled trial
  • clinical trial
  • smoking cessation